2024
Short term outcomes and resource utilization in de-novo versus acute on chronic heart failure related cardiogenic shock: a nationwide analysis
Quien M, Bae J, Jang S, Davila C. Short term outcomes and resource utilization in de-novo versus acute on chronic heart failure related cardiogenic shock: a nationwide analysis. Frontiers In Cardiovascular Medicine 2024, 11: 1454884. PMID: 39314766, PMCID: PMC11416976, DOI: 10.3389/fcvm.2024.1454884.Peer-Reviewed Original ResearchChronic heart failureIn-Hospital MortalityCardiogenic shockHeart failureAdvanced heart failure therapiesRight heart catheterizationEtiology of cardiogenic shockHeart failure therapyNon-ischemic etiologyProportion of patientsRenal replacement therapyShort-term outcomesReadmission mortalityNationwide Readmissions DatabaseMechanical circulatory supportCS subgroupsHeart catheterizationClinical courseFailure therapyReplacement therapyHeart transplantationTerm outcomesIn-HospitalCS casesReadmissions Database
2023
Patterns of Digoxin Prescribing for Medicare Beneficiaries in the United States 2013-2019
See C, Wheelock K, Caraballo C, Khera R, Annapureddy A, Mahajan S, Lu Y, Krumholz H, Murugiah K. Patterns of Digoxin Prescribing for Medicare Beneficiaries in the United States 2013-2019. American Journal Of Medicine Open 2023, 10: 100048. PMID: 38213879, PMCID: PMC10783702, DOI: 10.1016/j.ajmo.2023.100048.Peer-Reviewed Original ResearchDigoxin prescriptionDigoxin useNew heart failure therapiesGeneral medicine physiciansHeart failure therapyMedicare Part D dataPart D dataDigoxin prescribingFailure therapyPrescriber characteristicsMedicine physiciansMedicare beneficiariesPrescribersLikely maleLogistic regressionDigoxinNew prescribersPrescriptionRecent dataCardiologyIncreased length-dependent activation of human engineered heart tissue after chronic α1A-adrenergic agonist treatment: testing a novel heart failure therapy
Rupert C, López J, Cortez-Toledo E, De la Cruz Cabrera O, Chesler N, Simpson P, Campbell S, Baker A. Increased length-dependent activation of human engineered heart tissue after chronic α1A-adrenergic agonist treatment: testing a novel heart failure therapy. AJP Heart And Circulatory Physiology 2023, 324: h293-h304. PMID: 36637971, PMCID: PMC9886349, DOI: 10.1152/ajpheart.00279.2022.Peer-Reviewed Original ResearchConceptsHuman heart failureHeart failureAR stimulationChronic stimulationLength-dependent activationVehicle treatmentHeart tissueAdrenergic receptorsHuman EHTsAnimal heart failure modelNovel heart failure therapiesHeart failure therapyHeart failure modelMultiple preclinical modelsFailure therapyAgonist treatmentSeparate control experimentsPreclinical modelsDrug washoutTherapeutic effectTranslational significanceHuman myocardiumBaseline testingRNA-seq analysisPig myocardium
2022
Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice A Cluster Randomized Trial
Ghazi L, Yamamoto Y, Riello RJ, Coronel-Moreno C, Martin M, O'Connor KD, Simonov M, Huang J, Olufade T, McDermott J, Dhar R, Inzucchi SE, Velazquez EJ, Wilson FP, Desai NR, Ahmad T. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice A Cluster Randomized Trial. Journal Of The American College Of Cardiology 2022, 79: 2203-2213. PMID: 35385798, DOI: 10.1016/j.jacc.2022.03.338.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyUsual careEjection fractionHeart failureMedical therapyPrimary outcomeCluster-randomized comparative effectiveness trialSodium-glucose cotransporter 2 inhibitorsElectronic health record alertsAldosterone system inhibitorsReduced ejection fractionUsual care armCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsVentricular ejection fractionComparative effectiveness trialNumber of patientsKnowledge of guidelinesLow-cost interventionCare armDays postrandomizationEligible patientsGDMT useFailure therapyPatient characteristicsAssessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study
Pahuja M, Leifer ES, Clarke JD, Ahmad T, Daubert MA, Mark DB, Cooper L, Desvigne-Nickens P, Fiuzat M, Adams K, Ezekowitz J, Whellan DJ, Januzzi JL, O'Connor CM, Felker GM, Piña IL. Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. Progress In Cardiovascular Diseases 2022, 71: 79-85. PMID: 35490873, DOI: 10.1016/j.pcad.2022.04.010.Peer-Reviewed Original ResearchConceptsHeart failure hospitalizationNon-black patientsNT-proBNPBlack patientsFailure hospitalizationHigh riskKansas City Cardiomyopathy Questionnaire overall scorePre-specified subgroup analysisGUIDE-IT trialHigher NYHA classReduced ejection fractionNT-proBNP concentrationsHeart failure therapyNon-Hispanic patientsUsual clinical careImportant baseline covariatesQuality of lifeEthnicity-based differencesHF hospitalizationMore comorbiditiesNYHA classCause mortalityTriple therapyFailure therapyEjection fraction
2018
Specific Pro-Inflammatory Signaling Pathways are Induced in Patients with Cardiac Sarcoidosis; Potential Prognostic/Therapeutic Applications
Young B, Oatmen K, Freeburg L, Zellars K, Sapp A, Herzog E, Miller E, Spinale F. Specific Pro-Inflammatory Signaling Pathways are Induced in Patients with Cardiac Sarcoidosis; Potential Prognostic/Therapeutic Applications. Journal Of Cardiac Failure 2018, 24: s10. DOI: 10.1016/j.cardfail.2018.07.033.Peer-Reviewed Original ResearchCardiac sarcoidosisCardiac inflammationSarcoid patientsReceptor levelsEpidermal growth factorNormal subjectsSoluble tumor necrosis factor receptor IITumor necrosis factor receptor IIFluorodeoxyglucose positron emission tomographyPro-inflammatory signaling pathwaysAnti-inflammatory regimensMethods Plasma samplesHeart failure therapySoluble receptor levelsSpecific inflammatory pathwaysSpecific therapeutic targetingInflammatory signaling cascadesSpecific therapeutic targetsPositron emission tomographyCytokine receptor profilesCardiac involvementFailure therapyPrognostic valueTreatment regimensInflammatory pathwaysHypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe GW, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, Leiter LA, Jones C, Woo V, Hegele RA, Selby P, Pipe A, McFarlane PA, Oh P, Gupta M, Bacon SL, Kaczorowski J, Trudeau L, Campbell NRC, Hiremath S, Roerecke M, Arcand J, Ruzicka M, Prasad GVR, Vallée M, Edwards C, Sivapalan P, Penner SB, Fournier A, Benoit G, Feber J, Dionne J, Magee LA, Logan AG, Côté AM, Rey E, Firoz T, Kuyper LM, Gabor JY, Townsend RR, Rabi DM, Daskalopoulou SS, Canada H. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal Of Cardiology 2018, 34: 506-525. PMID: 29731013, DOI: 10.1016/j.cjca.2018.02.022.Peer-Reviewed Original ResearchConceptsBlood pressure monitoringTreatment of hypertensionBlood pressurePressure monitoringGuideline-directed heart failure therapyAmbulatory blood pressure monitoringHome blood pressure monitoringAngiotensin-converting enzyme inhibitorGlobal cardiovascular riskLarge arm circumferenceSetting of thrombolysisAngiotensin receptor blockersAcute ischemic strokeWhite-coat effectHeart failure therapyLower blood pressureUpper arm deviceEvidence-based guidelinesHypertension CanadaHypertension guidelinesReceptor blockersCardiovascular riskFailure therapyIschemic strokeHeart failure
2014
Characterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study
Gandhi PU, Szymonifka J, Motiwala SR, Belcher AM, Januzzi JL, Gaggin HK. Characterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study. Journal Of Cardiac Failure 2014, 21: 9-15. PMID: 25463415, DOI: 10.1016/j.cardfail.2014.10.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersCardiovascular AgentsChronic DiseaseDisease ManagementDizzinessFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsProspective StudiesQuality of LifeRenal InsufficiencySurveys and QuestionnairesTreatment OutcomeConceptsTreatment-related serious adverse eventsSerious adverse eventsQuality of lifeAdverse eventsRisk scoreN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideChronic heart failure managementHeart Failure Questionnaire scoreWorse QOLAcute renal failureFirst cardiovascular eventHeart failure managementHeart failure therapyWorse functional classHighest-risk quartileCare armHF careHF managementSystolic HFCardiovascular eventsNT-proBNPReverse remodelingFailure therapyRenal failure
2012
Impact of Community Wealth on Use of Cardiac-Resynchronization Therapy With Defibrillators for Heart Failure Patients
Farmer S, Tuohy E, Small D, Wang Y, Groeneveld P. Impact of Community Wealth on Use of Cardiac-Resynchronization Therapy With Defibrillators for Heart Failure Patients. Circulation Cardiovascular Quality And Outcomes 2012, 5: 798-807. PMID: 23093561, DOI: 10.1161/circoutcomes.112.965509.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac Resynchronization TherapyCardiac Resynchronization Therapy DevicesChi-Square DistributionCommunity Health ServicesDefibrillators, ImplantableEconomics, HospitalElectric CountershockFemaleHealth Care CostsHealth Services AccessibilityHealthcare DisparitiesHeart FailureHumansIncomeLinear ModelsLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioRegistriesResidence CharacteristicsRetrospective StudiesTreatment OutcomeUnited StatesConceptsCardiac resynchronization therapyHospital resourcesNational Cardiovascular Data RegistryHeart failure patientsHeart failure therapyPatient-level variablesMajor health policy concernFailure patientsFailure therapyInsurance statusHospital characteristicsPatient stayCardiovascular disease treatmentHealth policy concernData registryPatientsPatient volumeMedian household incomeHealth policyTherapyInsurance coverageSignificant predictorsDisease treatmentHospital ownershipAverage median household income
2003
Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure
Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM. Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure. JAMA 2003, 290: 81-85. PMID: 12837715, DOI: 10.1001/jama.290.1.81.Peer-Reviewed Original ResearchConceptsHeart failureDiabetic patientsConcomitant diabetesThiazolidinedione useMedicare beneficiariesRetrospective medical record abstractionUse of metforminAdvanced heart failureProportion of patientsHeart failure therapyMedical record abstractionAcute care hospitalsMetformin useFailure therapyHospital dischargeCare hospitalRecord abstractionOptimal carePrimary diagnosisAntihyperglycemic drugsMedicare patientsDrug treatmentPatterns of usePatientsPackage inserts
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply